Read the full stored bill text
hb966_00_IN
As Introduced
136th
General Assembly
Regular
Session
H. B. No. 966
2025-2026
Representative Somani
Cosponsors: Representatives Brennan,
Rader, Piccolantonio, Synenberg, White, E., Rogers
To
conduct
a study on the prevalence of cholestatic liver disorders in women.
BE
IT ENACTED BY THE GENERAL ASSEMBLY OF THE STATE OF OHIO:
Section
1.
(A)
The Department of Health shall conduct a statewide one-year study on
the prevalence of cholestatic liver disorders associated with
increased risk of end-stage liver disease among women ages
thirty-five through forty-five who are enrolled in the Ohio Medicaid
program. During the study, the Department shall collect all of the
following information on study participants:
(1)
Key demographics such as age, genetic predispositions, pre-existing
conditions, including autoimmune diseases and metabolic disorders,
and lifestyle factors that elevate an individual's risk of developing
cholestatic liver disorders;
(2)
The number or percentage of study participants who, despite being
identified as high-risk, do not follow through with medical referrals
or treatment recommendations;
(3)
The number of study participants who avoid referral and follow-up
care or otherwise engage in treatment avoidance;
(4)
Other relevant information or issues identified by the Department
related to cholestatic liver disorders associated with increased risk
of end-stage liver disease.
(B)(1)
Upon the conclusion of the one-year study, the Department shall
review the collected data and information and compile it into a
written report that includes both of the following:
(a)
Recommendations on how to increase awareness of cholestatic liver
disorders, including screenings and genetic testing, and collaborate
with patient advocacy groups to raise public awareness through social
media, seminars, and community outreach initiatives;
(b)
An analysis of strategies and funding to increase screening and
genetic testing for cholestatic liver disorders. The analysis must
include recommendations on how to promote public-private partnerships
to ensure sustainable funding for genetic research and testing
infrastructure.
(2)
All information collected and reported through the study shall be
handled in accordance with all applicable state and federal privacy
laws and regulations.
(3)
The Department of Health shall submit the report to the General
Assembly not later than December 31, 2028, and upon submission the
study is concluded.